UNSPSC 51173211: Carboxymethylcellulose/docusate/phenolphthalein

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA209. This VA Drug Class (GA209) classifies this compound as belonging to the group LAXATIVES, OTHER.

UNSPSC 51173211 Carboxymethylcellulose/docusate/phenolphthalein is a Commodity code that maps to laxative and bowel-preparation pharmaceutical products, but the recent state and local activity under this code does not reflect solicitation of the specific formulation named in the code itself. The three recent opportunities posted under or tagged to this code instead cover broader pharmaceutical procurement — offender drug-testing services using immunoassay and confirmatory testing methodologies, direct-to-manufacturer prescription program design, and generic multi-source pharmaceuticals and OTC products for cooperative purchasing. The activity suggests the code is being used to flag pharmaceutical-related procurements more broadly rather than to solicit the compound carboxymethylcellulose/docusate/phenolphthalein specifically. State and local issuing bodies using this code include county supervision and corrections departments (Collin County, Texas), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances serving state and local governments (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP).

Activity is concentrated in Texas and Minnesota. The most concrete recent opportunity is Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, with proposals due July 23, 2026 and an estimated contract value of $600,000 over two years with three optional one-year renewals. The Minnesota Department of Administration's MMCAP issued an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, establishing multi-awards across participating state and local government facilities in Minnesota and Oregon, with contract effectiveness of July 1, 2026. The Texas Health and Human Services Commission posted an RFI on direct-to-manufacturer prescription programs with a response deadline of April 3, 2026, seeking vendor capabilities for implementing a Therapeutic Pharmacy Initiative without a formal award value. The code shows recent activity but reflects procurement of pharmaceutical services and commodities at a higher level of generality than the specific compound named in the UNSPSC taxonomy.